Co-Founder, Kytos Therapeutics
Reuben Shaw is the Director of the NCI-Designated Basic Cancer Center at the Salk Institute for Biological Studies in La Jolla, California. Dr. Shaw got his PhD at MIT and did postdoctoral training at Harvard Medical School before starting as an Assistant Professor at the Salk in 2006. He was the recipient of several young investigator awards including the Howard Hughes Medical Institute Early Career Scientist Award. In August 2017, he received an NCI Outstanding Investigator Award. Research in the Shaw lab at the Salk Institute focuses on the LKB1-AMPK pathway, a central energy-sensing pathway in all cells that reprograms metabolism in low nutrient conditions, and which is altered in a large percentage of lung cancers. Decoding this cellular starvation pathway has led to many new therapeutic targets in cancer and metabolic disease.